STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

News

Stay informed with our latest news posts.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Weight loss breakthrough: how one woman lost 1.5 stone with Wegovy

Busy mum Annest found sustainable weight loss with Yazen. Four months in, she's healthier, confident, and embracing a positive, lasting lifestyle change.

Yazen raises €19.5m to expand obesity treatment in the EU

Yazen has secured €19.5 million in Series A funding to expand its GLP-1-based obesity treatment across Europe. The company combines medication with lifestyle support for sustainable weight loss results.

Yazen Health closes €19.5M series A to drive global growth

Yazen Health has successfully closed an oversubscribed €19.5 million series A funding round to fuel its international expansion. This investment enables Yazen to enhance its pioneering obesity treatment model, combining modern weight loss medication with comprehensive lifestyle support.

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

Lasker~DeBakey Award 2024 for groundbreaking GLP-1 obesity research

Riding the Wegovy wave: Startups shifting focus to GLP-1s to tap the $150bn weight loss drug market

GLP-1 weight loss drugs like Wegovy are attracting startups and investors, aiming to tap into the projected $150bn market despite supply and reimbursement challenges

The urgent need for strict warnings on ultra-processed foods - The Telegraph

Four foods that should come with a smoking-style health warning Some scientists believe ultra-processed food needs to be treated in a similar way to tobacco.

Expert opinions on sustainable weight loss: Insights from leading authorities

Join Health Tech World's webinar with experts discussing sustainable weight loss through medication, lifestyle changes, and digital health tools. Watch now!

Medical Product Alert: Fake Ozempic (semaglutide) Detected in Americas and Europe

Medical Product Alert: Fake Ozempic (semaglutide) Detected in Americas and Europe

Popular drug linked to reduced dementia risk in elderly with diabetes

Study shows GLP-1 agonists reduce dementia risk in elderly with type 2 diabetes. Findings from KI highlight potential benefits for diabetes treatment

Debunks myths surrounding obesity

Debunks myths surrounding obesity

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely

Wigan named UK's 'Fattest Town' - Yazen Health tackles obesity safely

Why do we not provide the care that morbidly obese individuals need?

The obesity epidemic is one of the greatest health challenges of our time. Globally, it is estimated that 1.9 billion people will suffer from morbid obesity by 2035, which represents one in four adults. Among children, obesity is expected to increase by 100 percent between 2020 and 2035. The cost to society is projected to be 4 trillion dollars.

Yazen participates in roundtable with Health Tech World

Martin Carlsson participates in "Where next for digital health? A roundtable debate hosted by Health Tech World

Yazen transforms the accessibility of obesity treatment: A new era in healthcare

Yazen tackles the challenge with groundbreaking, accessible, and comprehensive treatment approach

Shortages and concerns arise as weight-loss injections gain popularity

Weight-loss injections like Ozempic and Wegovy have gained significant attention, European startups entering market

60 tonnes of excess weight gone with a new method

Patients at the digital healthcare provider Yazen have now collectively shed 60 tonnes

No results found.
There are no results with this criteria. Try changing your search.